Opinion: FDA calls states’ bluffs on drug importation
Given the approach FDA is proposing on state-sponsored drug importation, it's a long shot that states will see significant savings, or even enough to justify the cost of setting up…
by Ian D. Spatz
Feb 18, 2020
3 minutes
For decades, critics of the U.S. drug pricing system have advocated importing drugs from Canada as a convenient shortcut to lower prices. The Food and Drug Administration’s recent release of a proposed regulation to create a process for approving state-sponsored importation plans is one step closer to that goal. A closer look shows that it’s actually a false step.
Career FDA staff, supported by previous FDA commissioners and Health and Human Services secretaries, have that there is no way to open a drug import channel into the U.S. pharmaceutical supply chain without violating the authorizing Canadian drug imports that required the FDA to certify that
You’re reading a preview, subscribe to read more.
Start your free 30 days